We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Whole-exome Sequencing Identifies Mysterious Pancreatitis Mutation

By LabMedica International staff writers
Posted on 06 Nov 2019
By applying advanced whole-exome sequencing analysis techniques, researchers have identified a mutation linked to a rare form of inhertied pancreatitis.

Pancreatitis is a disease that causes the pancreas to become inflamed, triggering severe abdominal pain. More...
Chronic pancreatitis can impede organ function, leading to diabetes and pancreatic cancer. The disease is most often caused by alcohol abuse, but several forms are caused by genetic mutations and are inheritable.

Recent evaluation of a patient with a strong family history of pancreatitis prompted investigators at the University of Chicago Medical Center and the University of California, San Francisco (USA) to reexamine a large kindred originally reported over 50 years ago with an autosomal-dominant inheritance pattern of chronic pancreatitis, diabetes, and pancreatic adenocarcinoma.

In 1968. physicians at the University of California, San Francisco evaluated 71 members of a family, then living in Northern California. Of the 18 people they examined, six were officially diagnosed with pancreatitis and another five were suspected of having the disease. Lack of technology at this time prevented identification of the gene responsible for the disease.

Now, more than half a century later, whole-exome sequencing analysis identified a rare missense mutation in the gene encoding the pancreas-specific protease elastase 3B (CELA3B) that cosegregates with disease. Laboratory experiments established that this mutation caused translational upregulation of CELA3B, which, upon secretion and activation by trypsin, leads to uncontrolled proteolysis and recurrent pancreatitis.

Despite the successful identification of the CELA3B mutation, the molecular basis of hereditary pancreatitis remains unknown for at least 30% of affected families.

“There are a lot of patients who still have what looks like inherited pancreatitis that do not have a genetic diagnosis - maybe some of these have mutations in elastase 3B,” said senior author Dr. Scott Oakes, professor of pathology at the University of Chicago Medical Center. “So, it has immediate implications not only for this family but potentially other families that have pancreatitis. The presentation is so dramatic it is possible that elastase 3B might be a good place to intervene in regular, garden-variety pancreatitis. If you could tamp it down, maybe you could help control the disease in other patients. This reinforces the advantage of seeing patients and running a lab: You can let human genetics drive our understanding of this disease. There are a lot of families like this in the medical literature where we still do not know the genetics. I think it is an exciting time now to figure out how to do that.”

The pancreatitis paper was published in the August 1, 2019, online edition of the Journal of Clinical Investigation.

Related Links:
University of Chicago Medical Center
University of California, San Francisco



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.